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Objective: Cardiovascular disease (CVD) is the most prevalent cause of mortality among patients with Type 1 or Type 2 diabetes, due to
accelerated atherosclerosis. Recent evidence suggests a strong link between atherosclerosis and insulin resistance due to impaired insulin
receptor (IR) signaling. Moreover, inﬂammatory cells, in particular macrophages, play a key role in pathogenesis of atherosclerosis and insulin
resistance in humans. We hypothesized that inhibiting the activity of protein tyrosine phosphatase 1B (PTP1B), the major negative regulator of the
IR, speciﬁcally in macrophages, would have beneﬁcial anti-inﬂammatory effects and lead to protection against atherosclerosis and CVD.
Methods: We generated novel macrophage-speciﬁc PTP1B knockout mice on atherogenic background (ApoE//LysM-PTP1B). Mice were fed
standard or pro-atherogenic diet, and body weight, adiposity (echoMRI), glucose homeostasis, atherosclerotic plaque development, and mo-
lecular, biochemical and targeted lipidomic eicosanoid analyses were performed.
Results: Myeloid-PTP1B knockout mice on atherogenic background (ApoE//LysM-PTP1B) exhibited a striking improvement in glucose ho-
meostasis, decreased circulating lipids and decreased atherosclerotic plaque lesions, in the absence of body weight/adiposity differences. This
was associated with enhanced phosphorylation of aortic Akt, AMPKa and increased secretion of circulating anti-inﬂammatory cytokine
interleukin-10 (IL-10) and prostaglandin E2 (PGE2), without measurable alterations in IR phosphorylation, suggesting a direct beneﬁcial effect of
myeloid-PTP1B targeting.
Conclusions: Here we demonstrate that inhibiting the activity of PTP1B speciﬁcally in myeloid lineage cells protects against atherosclerotic
plaque formation, under atherogenic conditions, in an ApoE/ mouse model of atherosclerosis. Our ﬁndings suggest for the ﬁrst time that
macrophage PTP1B targeting could be a therapeutic target for atherosclerosis treatment and reduction of CVD risk.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Despite extensive research and major advancements in modern
medicine, CVDs are still the leading cause of death worldwide ac-
counting for 17.3 million deaths globally per year (WHO Statistics,
http://www.who.int/mediacentre/factsheets/fs317/en/). Such diseases
are exacerbated by obesity and secondary pathologies such as Type 2
diabetes and atherosclerosis [1]; therefore, it is not surprising that the
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medium-sized arteries, and it is typically characterized by formation of
lesions, which can lead to arterial thrombosis and ischemic injury. The
proposed mechanisms that link accelerated atherosclerosis and
increased cardiovascular risk in diabetic and obese patients are poorly
understood. It has been suggested that an association between
hyperglycaemia and intracellular metabolic changes can result in
oxidative stress, low-grade inﬂammation, and endothelial dysfunction
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Original Articleatherosclerosis adding a further layer of complexity [2]. A better un-
derstanding of the mechanisms controlling these diseases is needed,
and more targeted and effective therapeutics are urgently sought.
In mice, deletion of the insulin receptor (IR) from vascular endothelial
cells in the apolipoprotein-E-deﬁcient mice (ApoE/) leads to an
increased rate of atherosclerosis development [3]. Moreover ApoE/
mice with a heterozygous deletion of the IR and its downstream target,
Insulin Receptor Substrate 1 (IRS1), also develop accelerated athero-
sclerosis [4], as well as mice lacking insulin receptor substrate 2
(IRS2/) [5]. Furthermore, decreased insulin signaling in non-
hematopoietic cells, as achieved by transplantation of ApoE/
mouse model of atherosclerosis with bone marrow cells from IRS1þ/
IRþ/ ApoE/ mice, contributed to increased atherogenesis in these
mice [4]. In all these disorders, macrophages play a key role driving the
pathology [6e9]; therefore, targeting their activity could prove
effective.
Protein tyrosine phosphatase (PTP)1B has been identiﬁed as the major
negative regulator of the IR itself [10]. In mice, whole body PTP1B/
studies established PTP1B as a major regulator of insulin sensitivity
and body mass, via inhibition of insulin and leptin signaling, respec-
tively [11,12]. Our recent research found that deletion of protein
tyrosine phosphatase 1B (PTP1B) within the myeloid cell lineage led to
protection against high-fat diet (HFD)-induced and bacterial toxin
(lipopolysaccharide LPS)-induced inﬂammation and hyperinsulinemia,
due to increased anti-inﬂammatory IL-10 and decreased pro-
inﬂammatory TNFa cytokine secretion in vivo [13]. Therefore, we
hypothesized that inhibiting the activity of PTP1B speciﬁcally in mac-
rophages, through genetic deletion, would have beneﬁcial anti-
inﬂammatory effects and lead to protection against atherosclerosis.
To assess this, we used the ApoE/ mouse model of atherosclerosis
under physiological and atherogenic conditions.
2. RESEARCH DESIGN AND METHODS
2.1. Animal studies
All animal procedures were performed under a project license
approved by the U.K. Home Ofﬁce under the Animals (Scientiﬁc Pro-
cedures) Act 1986 (PPL 60/3951). ApoE/ mice were bred in house,
and crosses were generated by breeding ApoE/ to mice devoid of
myeloid PTP1B (PTP1B-LysMCre as previously described [14]) to
generate ApoE//LysM-PTP1B. At 12 weeks of age, male and female
ApoE/ and ApoE//LysM-PTP1B mice were group housed (n¼ 3e
6 per cage) and placed on either chow or high fat diet (HFD 42% from
fat, 0.2% cholesterol, Envigo, Huntingdon UK) for 12 weeks. Mice were
maintained at 22e24 C on 12-h light/dark cycle with free access to
food/water. At week 12, mice were fasted for 5 h and injected with
either saline or insulin (10 mU/g body weight) for 10 min prior to culling
by CO2 inhalation and subsequent cervical dislocation. Heart and aortic
tissues were harvested and collected for further analysis. Tissues for
subsequent western blot or qPCR analysis were frozen in liquid ni-
trogen and stored at 80 C until needed, whereas tissues for his-
tology were immersed in formalin for 24 h at 4 C, then stored at 4 C
in PBS until analyzed.
2.2. Glucose and insulin tolerance tests
Mice were fasted for 5 h prior to commencement of glucose or insulin
tolerance tests (GTT and ITT, respectively). Brieﬂy, baseline glucose
levels were sampled from tail blood using glucose meters (AlphaTRAK,
Abbott Laboratories, Abbot Park, IL, USA). Subsequently mice were
injected I.P. with 20% glucose (w/v) or insulin (0.75 mU/g body weight)
and blood glucose measured at 15, 30, 60, and 90 min post-injection.846 MOLECULAR METABOLISM 6 (2017) 845e853  2017 The Authors. Published by Else2.3. Body fat mass composition
The body composition of each mouse was analyzed using an Echo
MRI-3-in-1 scanner (Echo Medical Systems, Houston, TX, USA). Mice
were placed individually into a plastic tube and inserted into the
scanner where total body fat and lean mass were determined.
2.4. Isolation and maturation of bone marrow derived
macrophages
Bone marrow derived macrophages (BMDMs) were isolated and
cultured as previously described [13]. Brieﬂy, following cervical
dislocation, the bone marrow was ﬂushed from the femurs and tibiae
using sterile phosphate buffered saline (PBS, Gibco) to disrupt the bone
marrow plugs and passed through a cell strainer. The cells were then
centrifuged at 1800g for 5 min and resuspended in red blood cell lysis
buffer before the reaction quenched with PBS and respun to pellet
cells. Cells were counted and seeded onto 6 well plates, at a density of
2 million per well, and cultured in complete media (DMEM (Gibco),
10% FBS (Invitrogen, Paisley, UK), 100 U/ml penicillin (Gibco) and
100 mg/ml streptomycin (Gibco)) supplemented with 20% L929-cell
conditioned medium) for 6 days (media was replaced on day 3) and
maintained at 37 C in a humidiﬁed atmosphere with 5% CO2. Mature
macrophages were harvested on day 6 for subsequent experiments.
2.5. Immunoblotting
Frozen aorta tissues were homogenized in 300 ml of ice-cold Radio-
immunoprecipitation assay (RIPA) buffer (10 mM TriseHCl pH 7.4,
150 mM NaCl, 5 mM EDTA pH 8.0, 1 mM NaF, 0.1% SDS, 1% Triton X-
100, 1% Sodium Deoxycholate with freshly added 1 mM NaVO4 and
protease inhibitors) using a PowerGen 125 homogenizer and lysates
normalized to 1 mg per 1 ml. Proteins were separated on a 4e12% Bis-
Tris gel by SDS-PAGE and transferred onto nitrocellulose membrane.
Membranes were probed for the following; p-IR (Tyr 1162/1163), IR b-
chain, p-AKT (Ser 473), p-p38 (The 181/Tyr 182), total p-38 p-S6 (Ser
235/236), total S6, p-AMPKa (Thr 172), total AMPKa, PTP1BandGAPDH.
2.6. Histology
Immediately following cervical dislocation, hearts were immersed in
formalin and stored at 4 C for 24 h before being transferred to PBS until
further analysis. Hearts were bisected to remove the lower ventricles,
frozen in OCT and subsequently sectioned at 5 mm intervals until the
aortic sinus was reached. Sections were mounted and stained with oil
red O to assess plaque formation. Images were captured using a light
microscope and plaque formation quantiﬁed using Image J software.
2.7. Serum analysis
Blood was collected during terminal procedures after fasting (5 h) and
spun to isolate serum, then stored at 80 C. Serum samples were
subsequently analyzed for insulin and IL-10 levels using ELISAs (Mil-
lipore and R&D Systems, respectively) or total cholesterol and tri-
glycerides (Sigma). For eicosanoid analysis, PGE2 was extracted from
serum in methanol and isolated by C18 solid-phase extraction chro-
matography. PGE2-d4 (Cayman Chemicals, Ann Arbor, MI, USA) was
added to the experimental system as an internal standard. PGE2 was
analyzed by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) using a TSQ Quantum Ultra triple quadrupole mass spec-
trometer coupled to an Accela 1250 UHPLC system (Thermo Scientiﬁc,
Hemel Hempstead, UK) in negative ion mode with a C18 column and
methanol-water gradient. Quantiﬁcation was performed using the
multiple reaction monitoring (MRM) mode using the transitions PGE2
(351/ 271) and PGE2-d4 (355/ 193). The concentration of PGE2
was determined by comparison to a calibration curve run in parallel.vier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.8. Statistical analysis
We expressed all values as mean S.E.M. We determined group sizes
by performing a power calculation to lead to an 80% chance of
detecting a signiﬁcant difference (p  0.05). For both in vivo and
ex vivo data, each n value corresponds to a single mouse. Statistical
analyses were performed by using one-way or Two-way ANOVA fol-
lowed by Tukey’s or Dunnett’s multiple-comparison tests to compare
the means of three or more groups or by an unpaired two-tailed
Student’s t-test to compare the means of two groups. Variances
were similar between groups. In all ﬁgures, */#p  0.05,
**/##p  0.01, ***/###p  0.001, ****p  0.0001. All analyses were
performed using GraphPad Prism (GraphPad Software).
3. RESULTS
3.1. Myeloid speciﬁc PTP1B knockout mice exhibit improved
glucose homeostasis independently of alterations in body weight/
adiposity
We recently demonstrated that myeloid PTP1B (LysM PTP1B) deletion
protected against LPS-induced inﬂammation and led to increased
production of the anti-inﬂammatory cytokine interleukin 10 (IL-10)
[14]. This intriguing ﬁnding compliments numerous studies implicating
IL-10 as having a protective role in atherogenesis and CVD (reviewed in
[15]). Given the importance of myeloid cells, particularly macrophages,
in the pathogenesis of both atherosclerosis and insulin signaling, we
sought to determine if PTP1B deletion in these cells would have
beneﬁcial protective effects against atherosclerosis development. To
achieve this, we generated novel myeloid-speciﬁc PTP1B knockout
mice using an atherogenic mouse model (ApoE//LysM-PTP1B) to
address this. These mice developed normally and did not display any
defects. To conﬁrm myeloid deletion, BMDMs from ApoE/ and
ApoE//LysM-PTP1B were harvested and probed for protein
expression of PTP1B (Figure 1A).
Myeloid-speciﬁc PTP1B knockout mice on an atherogenic background
(LysM-PTP1B/ApoE/) were placed on HFD for 12 weeks or chow as
a control. During this time, weight gain, body composition, glucose
tolerance, and insulin tolerance were assessed in both male and fe-
male mice from each genotype (Figure 1B). In contrast to global PTP1B
deletion [11], there were no differences in weight gain or body
composition between genotypes in either, male or female mice fed a
HFD (Figure 1 C, E, G and Figure 1 D, F, H respectively) or chow
(Supplemental Figure 1 A, B). As expected, male mice weighed more
than females with the greatest differences seen in lean mass (Figure 1
G, H), rather than fat mass (Figure 1 E, F), and gained more weight over
time. Despite no differences in weight gain, ApoE//LysM-PTP1B
animals exhibited markedly improved glucose tolerance when
compared to ApoE/, which was more pronounced in the female
mice (Figure 2 A, B). This improved glucose handling was maintained
at 6 (Figure 2 C, D) and 12 weeks (Figure 2 E, F) of HFD and again more
pronounced in females. When aged, 6 month old ApoE//LysM-
PTP1B chow fed mice still exhibited improved glucose handling when
compared to ApoE/ mice (Supplemental Figure 1C, D), in the
absence of body weight changes (Supplemental Figure 1 A, B).
Moreover, there was no difference between genotypes in HFD cohorts
when subjected to insulin tolerance tests (Figure 2 G, H), nor in
circulating insulin levels (Figure 2 I, J). The lack of difference in
circulating insulin levels was also observed in chow-fed mice
regardless of gender or genotype (Supplemental Figure 1 E, F). Given
these data, the improved glucose homeostasis could not be attributed
to differences in weight/adiposity and instead due to myeloid-speciﬁc
PTP1B deﬁciency.MOLECULAR METABOLISM 6 (2017) 845e853  2017 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.com3.2. Myeloid PTP1B deﬁciency on ApoE/ background results in
decreased cholesterol and triglyceride levels and protection against
diet-induced increase in atherosclerotic plaque area
Plaque formation in atherosclerosis is associated with lipid accumu-
lation within the vessels and arterial walls. Current treatments include
the use of lipid lowering drugs such as statins, which serve to reduce
levels within the blood. We found that total serum cholesterol was
decreased in ApoE//LysM-PTP1B female mice in both, HFD
(Figure 3A) and chow-fed (Supplemental Figure 2A) cohorts, whereas
triglyceride levels were signiﬁcantly decreased in female chow-fed
(Supplemental Figure 2B) and male HFD-fed (Figure 3B) ApoE/
/LysM-PTP1B mice.
The ultimate goal of this study was to test whether myeloid PTP1B
deﬁciency was sufﬁcient to protect against atherosclerotic plaque for-
mation. To assess this, sections of aorta, beginning at the aortic root,
were mounted and stained with Oil Red O. This revealed that there was
signiﬁcantly less plaque formation in ApoE//LysM-PTP1B mice when
compared to ApoE/ HFD mice, both in male and female mice,
although more prominent in females (Figure 3C, D). Therefore, we
demonstrate for the ﬁrst time that myeloid-PTP1B deﬁciency alone is
sufﬁcient to prevent atherosclerotic plaque formation under obesogenic,
HFD-feeding condition, on an atherogenic ApoE/ background.
3.3. Myeloid PTP1B deﬁciency on ApoE/ background results in
increased PGE2 and IL-10 secretion
Since we initially hypothesized that increased IL-10 levels associated
with myeloid-PTP1B deﬁciency may create an anti-inﬂammatory
environment and lead to protection against atherosclerosis develop-
ment, we next determined circulating levels of IL-10 in ApoE//LysM-
PTP1B and ApoE/ controls on chow and HFD. In agreement with our
hypothesis, whilst only one of the ApoE/ controls had any detectable
circulating IL-10 serum levels, IL-10 secretion was increased in
ApoE//LysM-PTP1B, male and female, HFD-fed mice (Figure 3E).
Similar data was observed in the aged chow-fed ApoE//LysM-
PTP1B females (Supplementary Fig. 2C). In addition, when male and
female data were combined, chow-fed ApoE//LysM-PTP1B exhibi-
ted a signiﬁcant increase in circulating levels of the eicosanoid,
prostaglandin E2 (PGE2) (Figure 3F), which has been recently impli-
cated as essential in switching macrophages from a pro-inﬂammatory
M1 to an anti-inﬂammatory M2 phenotype by stimulating IL-10 release
[16,17]. Although not signiﬁcant, a similar trend was observed when
the groups were separated by gender (Supplemental Fig. 2D). In
keeping with a decrease in pro-inﬂammatory signaling, we investi-
gated the expression of genes important in the inﬂammatory response.
More speciﬁcally, atherosclerotic plaque development is catalyzed by
an inﬁltration of leukocytes to the aortic tissues. Such events are
facilitated by monocyte chemoattractant protein-1 (MCP-1) and
adhesion molecules including intracellular cell adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), that
serve to recruit monocytes and facilitate their transmigration into the
vasculature, respectively [5]. To assess whether changes in the
expression of these genes within ApoE//LysM-PTP1B mice could
account for the decrease in plaque formation, we determined levels in
aortic tissue from our mouse groups (Supplemental Figure 2). While
there were no differences in aortic MCP-1 expression levels, ICAM
levels were higher in male HFD-fed ApoE//LysM-PTP1B mice in
comparison to chow-fed ApoE//LysM-PTP1B mice (Supplemental
Figure 3A), whilst VCAM-1 levels were upregulated in HFD-fed male
ApoE//LysM-PTP1B mice in comparison to ApoE/ mice
(Supplemental Figure 3C). In contrast, no signiﬁcant increases were
seen in the female ApoE//LysM-PTP1B mice, suggesting a less pro-open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 847
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Figure 1: Myeloid speciﬁc PTP1B deletion does not affect adiposity. (A) Western blot of bone marrow derived macrophages depicting deletion of PTP1B in LysM-PTP1B/
ApoE/ mice, GAPDH was used as a loading control. (B) Schematic representation of the experimental design. Mice were divided into ApoE/ or LysM-PTP1B/ApoE/ groups,
both males and females were tested (n ¼ 9e13 per group). Weekly body weights of male (C) and female (D) cohorts. Body composition was analyzed using an Echo MRI-3-in-1
scanner where total body fat (E, F) or lean mass (G, H) was determined (n ¼ 9e11 per group). Data are represented as mean  S.E.M. and analyzed by Two-way ANOVA followed
by Bonferonni multiple comparison t-tests.
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Figure 2: Myeloid speciﬁc PTP1B deletion improves glucose maintenance independently of weight gain in HFD fed and CHOW fed mice. Glucose tolerance tests at week
0, 6 and 12 of male (A, C, E) and female (B, D, F) mice fed HFD and insulin tolerance tests (G, H, male and female, respectively) at week 11. Mice were fasted for 5 h prior to basal
glucose monitoring (as described in materials and methods) and subsequently mice injected I.P. with 20% glucose (w/v) or insulin (0.75 mU/g body weight) and blood re-analyzed
at 15, 30, 60 and 90 min post-injection. Blood was collected at terminal culls and serum analyzed for circulating insulin levels (I, J) using ELISA (Millipore). Data are represented as
mean  S.E.M. (n ¼ 7 per group) and analyzed by unpaired two-tailed t-tests or two-way ANOVA followed by Bonferroni multiple comparison t-tests where *p  0.05, **p  0.01,
****p  0.0001 when compared to ApoE/ control groups.
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Figure 3: Myeloid speciﬁc PTP1B deletion reduces serum cholesterol and triglycerides and reduces atherosclerotic plaque formation. Blood was collected at terminal
culls and serum analyzed for circulating total cholesterol (A) triglyceride levels (B) using ELISA (Millipore) (C) Representative (n ¼ 5e6 per group) aortic root sections stained with
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and analyzed by one-way ANOVA, followed by unpaired two-tailed t-tests where *p  0.05 and **p  0.01, when compared to ApoE/ control groups.
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inﬂammatory environment in female mice, which could explain the
more pronounced reduction in plaque formation when compared to
female ApoE/ controls.
3.4. Myeloid PTP1B deﬁciency on ApoE/ background is
associated with hyperphosphorylation of Akt and AMPKa1 in the
aorta
Previous studies using ApoE/ mice heterozygous for both IR and the
insulin receptor substrate-1 (IRS1) protein found that the
apolipoprotein-E deﬁciency resulted in increased atherosclerosis
development [4]. A similar phenotype was noted when IRS2 was
deleted within the same ApoE/ background [5]. Given these data,
we hypothesized that an upregulation of IR signaling and associated
downstream pathways could account for the beneﬁcial effects of
PTP1B deletion in our study. Therefore, we investigated the IR
signaling pathway in aortic tissues. In contrast to our hypothesis, there
were no detectable differences in phosphorylation of the IR itself in
aortic tissue from either chow-fed (Figure 4 A, C, F, H) or HFD-fed
(Figure 4 B, C, G, H) ApoE//LysM-PTP1B and ApoE/ mice.
However, there was a striking enhancement of downstream signaling,
as indicated by hyperphosphorylation of Akt, in both male and female
ApoE//LysM-PTP1B mice (Figure 4 A, B, D & F, G, I). As expected,
HFD-feeding resulted in a blunted response to insulin-stimulated Akt
phosphorylation in both males (Figure 4D) and females (Figure 4I), and
in females, insulin was able to stimulate Akt phosphorylation only in
ApoE//LysM-PTP1B mice (Figure 4I). Male ApoE//LysM-PTP1B
mice also exhibited enhanced pS6 signaling (Supplemental Figure. 3 A,
B, C & F, G, H). Considering that IL10 has recently been shown to
directly phosphorylate and activate AMPKa [18] and that IL-10
secretion is upregulated in ApoE//LysM-PTP1B mice, we postulated
that these mice may exhibit alterations in AMPKa activation. Consistent
with this notion, AMPKa activation in male chow fed aortic tissue was
upregulated under basal condition in ApoE//LysM-PTP1B mice
(Figure 4 A, E), and pAMPKa signaling was enhanced in female chow
and HFD-fed insulin-stimulated ApoE//LysM-PTP1B mice (Figure 4
A, B, E & F, G, J). These data suggest that myeloid-PTP1B deﬁ-
ciency induces AMPK activation. We observed no differences in p38
phosphorylation across genotype or gender (Supplemental Figure 4 A,
B, F, G). Furthermore, there were no differences in aortic-PTP1B
protein levels, as expected and consistent with myeloid-speciﬁc
PTP1B deﬁciency (Supplemental Figure 3 E, J). Therefore, since the
deletion is limited to the myeloid cell lineage, the increase in aortic Akt
and AMPKa phosphorylation can be attributed solely to myeloid-
speciﬁc PTP1B deﬁciency.
4. DISCUSSION
In conclusion, we demonstrate here that myeloid-speciﬁc genetic
deletion of PTP1B in the ApoE/ mouse model of atherosclerosis
leads to protection against atherosclerosis development, suggesting
beneﬁcial effects of PTP1B inhibition for the reduction of cardiovas-
cular risk and treatment of CVDs. We present evidence that myeloid-
PTP1B deﬁciency results in activation of aortic Akt and AMPKa1,
without measurable alterations in insulin receptor phosphorylation. We
also demonstrate that myeloid-speciﬁc PTP1B deﬁciency on an ApoE/
 background leads to improved glucose maintenance, independently
of body weight/adiposity differences, and that this results in increased
circulating levels of the anti-inﬂammatory cytokine IL-10, and the
vasodilator eicosanoid PGE2. Finally, we present evidence, for the ﬁrst
time, that demonstrates that myeloid-PTP1B targeting results in a
decrease in circulating serum cholesterol (female mice under chowMOLECULAR METABOLISM 6 (2017) 845e853  2017 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comand HFD-feeding conditions) and triglyceride levels (female mice on
chow diet and male mice on HFD diet) and protection against
atherosclerotic plaque formation.
Our data compliment a recent study by Kandadi et al. [19] that found
whole body PTP1B deletion improved cardiomyocyte contractility in
mice fed HFD, through an AMPK-dependent mechanism. Furthermore,
myeloid-speciﬁc deletion of AMPKa1 on an LDLR/ mouse back-
ground, resulted in hypercholesterolemia, increased macrophage
inﬂammation and plaque inﬁltration and exacerbated atherogenesis
[20]. Thus, the increase we observe in aortic AMPKa1 phosphorylation
with myeloid-PTP1B deﬁciency, and associated protection against
atherosclerotic plaque accumulation, suggest that PTP1B inhibition
may be anti-atherogenic through an AMPKa1-driven mechanism and
warrants investigation in future studies.
In further support of PTP1B inhibition as a potential therapeutic target
for atherosclerosis, we have previously demonstrated that hepatic-
PTP1B deﬁciency was sufﬁcient to protect against HFD-induced
endothelial dysfunction, in the absence of any changes in body
mass/adiposity [21]. Considering that endothelial dysfunction acts as
an independent predictor of cardiovascular events, this was ﬁrm evi-
dence that PTP1B inhibition may not only play an anti-diabetic role, but
also hold potential for treatment of CVDs.
Critically, atherosclerosis is now well regarded as a chronic inﬂammatory
disease with current anti-inﬂammatory therapeutics aimed at targeting
speciﬁc parts of the cascade [22]. Moreover, recent studies have focused
on macrophages and, in particular, promotion from pro-inﬂammation to
pro-resolution, as a means to reduce atherogenesis and similar chronic
inﬂammatory pathologies [23,24]. Indeed, the anti-inﬂammatory cyto-
kine IL-10, which promotes resolution by stimulating efferocytosis and
tissue repair, is now being engineered as nanoparticles to allow more
speciﬁc targeting, and has resulted in the stabilization of the ﬁbrous cap
and necrotic core reduction in HFD-fed LDLR/mice [25]. Furthermore,
a recent study by Zhu et al. [18] found that IL-10 stimulation of AMPKa
phosphorylation and subsequent downstream PI3K/Akt/mTORC1
signaling was critical for eliciting the anti-inﬂammatory properties of this
cytokine. In support of these data, a previous study from our lab found
myeloid-deletion of PTP1B resulted in increased anti-inﬂammatory
signaling, as evidenced by a decrease in pro-inﬂammatory IL-6 and
TNFa, and an increase in pro-resolution IL-10 [14].
Our targeted lipidomic eicosanoid analysis revealed a speciﬁc increase
in circulating PGE2 levels; an eicosanoid essential in eliciting the pro-
inﬂammatory cascade. In contrast to its role as a pro-inﬂammatory
molecule, recent research has implicated PGE2 to behave as an
immunomodulator, acting on four distinct G-protein coupled receptors
(GPCRs, EP1-4) to both, inhibit and stimulate, the synthesis of pro- and
anti-inﬂammatory cytokines, respectively. Importantly, PGE2 has been
found to be essential in switching macrophages from a pro-
inﬂammatory M1 to an anti-inﬂammatory M2 phenotype and does so
through an IL-10 dependent mechanism [16,17]. In addition, deletion of
PTP1B enhances the expression of COX2, which is upstream of PGE2
release [26], and was found to be protective against endothelial
dysfunction in a model of Type 1 diabetes. Finally, PGE2 has been
implicated in providing a protective role in diet-induced obesity and
metabolic syndrome, critical for white to brown fat conversion [27].
In conclusion, the data presented herein, demonstrate that aortic Akt
and AMPKa signaling was enhanced in response to genetic deletion of
myeloid-PTP1B on ApoE/ background, and accompanied by
increased circulating levels of the anti-inﬂammatory cytokine IL-10 and
the vasodilator eicosanoid, PGE2. Given these ﬁndings, the beneﬁcial
effects of PTP1B inhibition on the atherogenesis process is likely to be
through an IR-independent, PGE2/IL-10/AMPKa-driven mechanism.open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 851
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Figure 4: Myeloid speciﬁc PTP1B deletion improves Akt and AMPK signaling in CHOW-fed and HFD-fed mice (A, B, F, G) Western blot analysis of aortic tissues from male
(A, B) and female (F, G) ApoE/ or LysM-PTP1B/ApoE/ mice fed either chow (A, F) or HFD (B, G) and injected with either saline or insulin immediately prior to culling.
Quantiﬁcation of p-IR (Tyr 1162/1163) (C, H), p-Akt (Ser 473) (D, I) and p-AMPKa (Thr 172) (E, J) of male and females represented in A, B and F, G respectively. Data are
represented as mean  S.E.M. and analyzed by one way ANOVA followed by Dunnets post hoc analysis or unpaired two-tailed t-tests where *p  0.05, **p  0.01, ***p  0.01
when compared to saline or ApoE/ control groups.
Original ArticleTherefore, based on our data, we propose that PTP1B inhibitors,
currently in pre-clinical trials for Type 2 diabetes and breast cancer
[28], could be repurposed for the treatment of atherosclerosis and
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